Highlights•High/low bone density in rare human diseases have been linked to mutations in
components of WNT signaling.•Mutations in the receptors LRP4, 5 or 6 affect their affinity for …

Sclerosteosis and van Buchem disease (VBD) are two rare autosomal recessive disorders
that results from osteoblast hyperactivity, in which progressive bone overgrowth leads to …

Bone mineral density (BMD) assessed by DXA is used to evaluate bone health. In children,
total body (TB) measurements are commonly used; in older individuals, BMD at the lumbar …

Sclerostin is a well-known inhibitor of bone formation that acts on Wnt/β-catenin signaling.
This manuscript considers the possible role of sclerostin in vascular calcification, a process …

The WNT pathway has become an attractive target for skeletal therapies. High-bone-mass
phenotypes in patients with loss-of-function mutations in the LRP5/6 inhibitor Sost …

As the vertebrate skeleton develops it progresses from a solely cartilaginous scaffold to a
mineralized bony skeleton. The cells that build up the skeleton, the chondrocytes and …

Osteoporosis and cardiovascular diseases are major public health issues. Bone and
cardiovascular remodeling share multiple biological markers and pathways. Medical …

Sclerostin, a 22-kDa glycoprotein that is mainly secreted by the osteocytes, is a soluble
inhibitor of canonical Wnt signaling. Therefore, when present at increased concentrations, it …

The Wnt pathway is involved in several processes essential for bone development and
homeostasis. For proper functioning, the Wnt pathway is tightly regulated by numerous …

Osteoporosis is caused by increased bone resorption and decreased bone formation.
Intermittent administration of a fragment of Parathyroid hormone (PTH) activates osteoblast …